Skip to main
BRKR
BRKR logo

Bruker (BRKR) Stock Forecast & Price Target

Bruker (BRKR) Analyst Ratings

Based on 26 analyst ratings
Buy
Strong Buy 31%
Buy 15%
Hold 50%
Sell 4%
Strong Sell 0%

Bulls say

Bruker Corporation is expected to have an adjusted EPS increase of 11-13%, indicating strong financial performance and a favorable outlook for profitability. The company reported organic revenue growth of 4.5%, significantly surpassing market consensus, while also achieving a 3.9% growth in overall revenues, highlighting robust demand across its segments. Additionally, improvements in adjusted gross margins, coupled with a solid backlog and growth drivers such as semi-metrology, further position Bruker favorably in the scientific instruments and diagnostics market.

Bears say

Bruker Corporation has faced a decline in organic revenue within its Supercon Technologies (BEST) segment, posting a 2.8% decrease and raising concerns regarding its growth prospects in a challenging market environment. The potential for reduced funding from the NIH, projected to decrease by 8-10% and contribute nearly $15 million in lost revenue, coupled with uncertainties surrounding competition and demand in key regions, particularly Europe, indicates heightened risks to future earnings. Furthermore, ongoing legal challenges regarding the GeoMx injunction may adversely impact instrument sales and create additional headwinds for the company through fiscal year 2025.

Bruker (BRKR) has been analyzed by 26 analysts, with a consensus rating of Buy. 31% of analysts recommend a Strong Buy, 15% recommend Buy, 50% suggest Holding, 4% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bruker and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bruker (BRKR) Forecast

Analysts have given Bruker (BRKR) a Buy based on their latest research and market trends.

According to 26 analysts, Bruker (BRKR) has a Buy consensus rating as of Jul 13, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bruker (BRKR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.